Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Compugen

Evaluate

Thumbnail
June 08, 2023

Asco 2023 movers – maintaining the momentum

Several biotech stocks maintained throughout Asco the momentum they had going into the meeting, and intrigue over Tigit continued.

May 30, 2023

Asco 2023 preview – Tigit lives again

An obscure Roche dataset reignites the Tigit space, and sends up Arcus, Compugen and Iteos.

Article image
Vantage logo
February 09, 2023

Astra tentatively takes Tigit pivotal

Bispecifics targeting Tigit and CTLA4 head into phase 3 development, as the developer follows Bristol out of IL-12.

Article image
Vantage logo
December 20, 2022

A success for Tigit? Not quite

The Arc-7 trial might be a numerical success, but Roche’s experience will weigh heavy.

Article image
Vantage logo
June 05, 2022

Asco 2022 – investors clutch at the Tigit straws

Roche’s SCLC study is an unmitigated disaster, but investors holding out for success in NSCLC are thrown a crumb of comfort.

Article image
Vantage logo
May 27, 2022

Asco 2022 – great expectations for Adicet, Arcellx and PMV

Unveiled abstracts from Asco lift the stock of several biotechs, which will now be under pressure not to disappoint at the conference next week.

Article image
Vantage logo
May 11, 2022

Looking beyond Roche’s Tigit bombshell

The failure of Skyscraper-01 calls into question Roche’s vast investment in Tigit blockade, but is there broader significance?

Article image
Vantage logo
March 30, 2022

Roche’s Tigit fail poses a big question for Merck

Roche just showed that adding Tigit to PD-(L)1 blockade is a non-starter in SCLC, and now Merck & Co risks doing the same.

Article image
Vantage logo
November 18, 2021

Arcus’s near dream scenario

Gilead opts in at long last, and that’s more than many might have been expecting.

Article image
Vantage logo
November 12, 2021

Astra presses on with bispecifics

Followers of novel immuno-oncology mechanisms will note Astrazeneca as a new player in Tigit and Tim3.

Article image
Vantage logo
September 29, 2021

Crucial clinical events for the smaller players

Data are due in the fourth quarter for Aldeyra, Aeglea and Radius, among other small developers.

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up